Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat for Crohn's Disease, Ulcerative Colitis, and Chronic Granulomatous Disease Colitis
NCT03167437Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2017
- Primary completion
- Jun 2035
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in Crohn's disease, ulcerative colitis (UC), chronic granulomatous disease (CGD), sponsored by National Institute of Allergy and Infectious Diseases. Started Oct 2017; status: recruiting.
02
Drugs
vorinostat
03
Conditions
Crohn's diseaseulcerative colitis (UC)chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on NCT03167437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03167437.